Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

This study has been terminated.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: April 16, 2013
Last updated: September 23, 2014
Last verified: September 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)